發(fā)布時(shí)間：2018-05-06 07:39

  本文選題：肺腫瘤 + 手術(shù)治療�。� 參考：《中國(guó)肺癌雜志》2017年02期

【摘要】：背景與目的小細(xì)胞肺癌(small cell lung cancer,SCLC)占所有肺癌的比例近15%左右。SCLC作為一種高度侵襲性腫瘤,惡性程度高,轉(zhuǎn)移早而廣泛,對(duì)化療、放療敏感,初治緩解率高,但容易復(fù)發(fā),如果未經(jīng)任何治療,其中位生存期僅為4個(gè)月-6個(gè)月。近年來(lái)對(duì)SCLC開(kāi)展了許多研究,但仍未改變SCLC的臨床治療策略,治療上仍局限于諸如足葉乙甙+順鉑(EP)或卡鉑(CE)化療方案等一些經(jīng)典的治療手段,對(duì)手術(shù)治療在SCLC治療,尤其是Ⅲa期的治療仍未達(dá)成共識(shí)。本研究旨在探討Ⅲa期SCLC的外科手術(shù)為主的綜合治療對(duì)SCLC的臨床治療效果及對(duì)影響預(yù)后的因素。方法通過(guò)回顧性分析1995年1月-2010年12月首都醫(yī)科大學(xué)附屬北京胸科醫(yī)院收治手術(shù)治療的78例SCLC患者的臨床資料。對(duì)患者進(jìn)行隨訪,全組病例對(duì)性別、年齡、腫瘤大小、淋巴結(jié)轉(zhuǎn)移狀況、腫瘤-淋巴結(jié)-轉(zhuǎn)移(tumor-node-metastasis,TNM)分期、手術(shù)方式及術(shù)后輔助放化療進(jìn)行統(tǒng)計(jì)學(xué)分析其手術(shù)治療與預(yù)后的關(guān)系。結(jié)果本組78例患者中位生存期為13.93個(gè)月,術(shù)前新輔助化療47例,中位生存期為14.25個(gè)月;術(shù)后輔助化療31例,中位生存期為13.83個(gè)月;兩者無(wú)統(tǒng)計(jì)學(xué)差異。單站單個(gè)(微轉(zhuǎn)移)淋巴結(jié)轉(zhuǎn)移28例中位生存期為17.1個(gè)月,多站多個(gè)淋巴結(jié)轉(zhuǎn)移(廣泛轉(zhuǎn)移)50例,中位生存期為11.9個(gè)月。兩者有明顯統(tǒng)計(jì)學(xué)差異(P0.01)。結(jié)論進(jìn)一步評(píng)價(jià)外科治療在SCLC綜合治療中的地位及價(jià)值,對(duì)于Ⅲa期SCLC,以手術(shù)為主的綜合治療可以使部分患者受益。
[Abstract]:Background & objective small cell lung cancer (SCLC) accounts for nearly 15% of all lung cancers. As a highly invasive tumor, it has high malignancy, early metastasis and extensive metastasis. It is sensitive to chemotherapy and radiotherapy, and has a high initial remission rate, but it is prone to relapse. If there is no treatment, the survival time is only 4-6 months. In recent years, many studies have been carried out on SCLC, but the clinical treatment strategy of SCLC has not been changed, and the treatment is still limited to some classical treatment methods such as the chemotherapy regimen such as cisplatin or carboplatin, and so on. The surgical treatment is used in SCLC. In particular, no consensus has been reached on the treatment of stage 鈪，

本文編號(hào)：1851401